The estimated Net Worth of Alex Nemiroff is at least $2.28 Millón dollars as of 13 June 2022. Mr Nemiroff owns over 7,500 units of Praxis Precision Medicines stock worth over $2,279,765 and over the last 4 years he sold PRAX stock worth over $0.
Mr has made over 1 trades of the Praxis Precision Medicines stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of PRAX stock worth $12,225 on 13 June 2022.
The largest trade he's ever made was buying 7,500 units of Praxis Precision Medicines stock on 13 June 2022 worth over $12,225. On average, Mr trades about 469 units every 0 days since 2021. As of 13 June 2022 he still owns at least 39,347 units of Praxis Precision Medicines stock.
You can see the complete history of Mr Nemiroff stock trades at the bottom of the page.
Alex Nemiroff J.D. is the Gen. Counsel & Sec. at Praxis Precision Medicines.
Mr D is 42, he's been the Gen. Counsel & Sec. of Praxis Precision Medicines since . There are 3 older and no younger executives at Praxis Precision Medicines. The oldest executive at Praxis Precision Medicines, Inc. is Dr. Bernard Ravina, 54, who is the Chief Medical Officer.
Alex's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Over the last 4 years, insiders at Praxis Precision Medicines have traded over $16,246,895 worth of Praxis Precision Medicines stock and bought 242,294 units worth $603,092 . The most active insiders traders include Holdings A/S Novo, Parallel Master Fund L.P.Bl... y Dean J Mitchell. On average, Praxis Precision Medicines executives and independent directors trade stock every 48 days with the average trade being worth of $3,178,530. The most recent stock trade was executed by Jill De Simone on 5 October 2023, trading 14,500 units of PRAX stock currently worth $25,375.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Praxis Precision Medicines executives and other stock owners filed with the SEC include: